Oxidized apolipoprotein B-100 (oxApoB-100)

Oxidized apolipoprotein B-100 is a modified form of the structural protein found in low-density lipoprotein (LDL) particles, occurring primarily through oxidative stress in the arterial subendothelial space (Witztum & Steinberg, 1991). While native apolipoprotein B-100 is essential for cholesterol transport via the LDL receptor, its oxidized counterpart is recognized by scavenger receptors on macrophages, such as CD36 and LOX-1 (Gleissner et al., 2007). This unregulated uptake leads to the accumulation of cholesterol within macrophages, turning them into foam cells, which are central to the development and progression of atherosclerotic plaques (Lusis, 2000). Oxidized apolipoprotein B-100 also acts as a potent DAMP (damage-associated molecular pattern), triggering chronic inflammatory and immune responses within the vessel wall (Nilsson et al., 2012). Therapeutic strategies, including monoclonal antibodies like MLDL1278A and vaccines like CVX-210, aim to neutralize these oxidized epitopes to reduce vascular inflammation and the risk of acute cardiovascular events (Schiopu et al., 2004; Genentech, 2012). As a major driver of atherogenesis, it serves as both a critical biomarker for oxidative stress and a promising target for immunomodulatory cardiovascular therapies (Ylä-Herttuala et al., 2012).

Other names

Oxidized ApoB-100Malondialdehyde-modified apolipoprotein B-100MDA-ApoB-100Oxidized LDL-ApoBoxLDL-ApoB100Apolipoprotein B-100, oxidized

Monoclonal antibodies and vaccines target oxidized apolipoprotein B-100 to neutralize its pro-inflammatory epitopes and block its uptake by macrophage scavenger receptors, thereby preventing foam cell formation and stabilizing atherosclerotic plaques (Schiopu et al., 2004; Nilsson et al., 2012).